We are pleased to share positive topline Phase II results from our investigational dual GLP-1/GIP receptor agonist in people living with type 2 diabetes, obesity or overweight. Read more here: spkl.io/60197Tn6V$ROG$RHHBY#Obesity
#MEDIA - We are pleased to share that the European Commission (EC) has approved our continuous delivery treatment for adults with neovascular age-related macular degeneration (#nAMD), offering an alternative to standard-of-care eye injections. roche.com/media
#MEDIA –The CHMP has recommended approval of our multiple sclerosis treatment for young people aged 10+ living with relapsing MS in the EU, who have limited options today.
👉spkl.io/60107T3w4#multiplesclerosis#MS
#MEDIA – We are pleased to announce that the phase III study met its primary endpoint, significantly improving progression-free survival for people with second-line or later relapsed or refractory #FollicularLymphoma#Hematologyspkl.io/60157rk3h$ROG$RHHBY
Finding faint molecular clues early is critical for cancer research. Sequencing by expansion (SBX) technology can help researchers detect traces of circulating tumor DNA (ctDNA) to help reveal how tumors grow, change and react to treatment.
Learn how: go.roche.com/xgensbx
